ReviewTranslational research : the journal of laboratory and clinical medicine2018
Serum biomarkers for diagnosis and prediction of type 1 diabetes.
Review in Translational research : the journal of laboratory and clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Clinical parameters and emerging biomarkers of partial remission in pediatric type 1 diabetes: a systematic review.Frontiers in endocrinology · 2026Pooled it
- Inflammatory Mediators in the Oral Fluids and Blood Samples of Type 1 Diabetic Patients, According to Periodontal Status-A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Circulating biomarkers during progression to type 1 diabetes: A systematic review.Frontiers in endocrinology · 2023Pooled it
- Exploratory bioinformatics analysis for identifying candidate biomarkers of type 1 diabetes mellitus.PeerJ · 2026Article
- Emerging Biomarkers and Nanobiosensing Strategies in Diabetes.Biosensors · 2025Review
- Biomarkers, Proteoforms, and Mass Spectrometry-Based Assays for Diabetes Clinical Research.The Journal of clinical endocrinology and metabolism · 2025Review
- Article
- Recent advances in early diagnosis and treatment of T1D with miRNAs.Frontiers in endocrinology · 2025Review
- Investigation on Phenomics of Traditional Chinese Medicine from the Diabetes.Phenomics (Cham, Switzerland) · 2024Review
- Insulitis in human type 1 diabetes: lessons from an enigmatic lesion.European journal of endocrinology · 2024Article
- Small molecule inhibitors target multiple neuropathological signaling to exert novel neuroprotection in intracranial aneurysms.Frontiers in pharmacology · 2024Review
- Multi-omics Investigations in Endocrine Systems and Their Clinical Implications.Advances in experimental medicine and biology · 2024Article
- Immunomodulatory nano-preparations for rheumatoid arthritis.Drug delivery · 2023Review
- Targeted serum proteomics of longitudinal samples from newly diagnosed youth with type 1 diabetes distinguishes markers of disease and C-peptide trajectory.Diabetologia · 2023Article
- ANPELA: Significantly Enhanced Quantification Tool for Cytometry-Based Single-Cell Proteomics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Selected Serum Markers Associated with Pathogenesis and Clinical Course of Type 1 Diabetes in Pediatric Patients-The Effect of Disease Duration.Journal of clinical medicine · 2023Article
- Pathological mechanisms of type 1 diabetes in children: investigation of the exosomal protein expression profile.Frontiers in endocrinology · 2023Article
- Metabolomics and Lipidomics Studies in Pediatric Type 1 Diabetes: Biomarker Discovery for the Early Diagnosis and Prognosis.Pediatric diabetes · 2023Review
- Posttranslational modifications in diabetes: Mechanisms and functions.Reviews in endocrine & metabolic disorders · 2022Review
- Recent developments of neuroprotective agents for degenerative retinal disorders.Neural regeneration research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 diabetes (T1D) culminates in the autoimmune destruction of the pancreatic βcells, leading to insufficient production of insulin and development of hyperglycemia. Serum biomarkers including a combination of glucose, glycated molecules, C-peptide, and autoantibodies have been well established for the diagnosis of T1D. However, these molecules often mark a late stage of the disease when ∼90% of the pancreatic insulin-producing β-cells have already been lost. With the prevalence of T1D increasing worldwide and because of the physical and psychological burden induced by this disease, there is a great need for prognostic biomarkers to predict T1D development or progression. This would allow us to identify individuals at high risk for early prevention and intervention. Therefore, considerable efforts have been dedicated to the understanding of disease etiology and the discovery of novel biomarkers in the last few decades. The advent of high-throughput and sensitive "-omics" technologies for the study of proteins, nucleic acids, and metabolites have allowed large scale profiling of protein expression and gene changes in T1D patients relative to disease-free controls. In this review, we briefly discuss the classical diagnostic biomarkers of T1D but mainly focus on the novel biomarkers that are identified as markers of β-cell destruction and screened with the use of state-of-the-art "-omics" technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.